Investigation Overview
The announcement that Pharmasset, Inc. agreed to be acquired by Gilead Sciences, Inc for $137 per share prompted an investigation on behalf of investors of Pharmasset, Inc. (NASDAQ: VRUS) concerning whether the offer to acquire Pharmasset and the buyout process are unfair to investors of Pharmasset (NASDAQ:VRUS) and whether certain of its officers and directors or others breach their ...
You must register (for free) or login to view the entire investigation.